CTLA4 and cancer: Currently, three immunomodulatory antibodies targeting CTLA-4 (ipilimumab (Yervoy®; Bristol-Myers Squibb)) and PD-1 (nivolumab (Opdivo®; Bristol-Myers Squibb), and pembrolizumab (Keytruda®; Merck Sharp & Dohme Corp)) have gained accelerated approval by the U.S FDA for metastatic melanoma and non-small cell lung cancer (Keytruda®) but no doubts that they will be soon accepted for other types of cancer (for a detailed review see [123]).